The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Open accessPublished version of a preprint
Abstract
Natural killer (NK) cells are immune cells sensing and eliminating foreign, stressed, transformed, and senescent cells through specialized surface receptors, such as NKG2D, that interacts with several virus- or stress-inducible ligands, including ULBP1 and -2, which are expressed on target cell surfaces. For example, induction of DNA damage or cellular senescence pathways in tumor cells led to upregulation of NKG2D ligands that activate NK cells. Although, both pathways activate p53, the relationship of p53 activation to upregulation of NKG2D ligands has not been addressed. In this study, we report that induction of wild-type p53, but not mutant p53, strongly upregulated mRNA and cell surface expression of ULBP1 and -2, whereas expression of other NK cell ligands was not affected. We defined intronic p53-responsive elements in these two novel p53 target genes. Coculture of wild-type p53-induced human tumor cells with primary human NK cells enhanced NKG2D-dependent degranulation and IFN-γ production by NK cells. Accordingly, treatment of certain wild-type p53-expressing tumor cell lines with the p53-reactivating small molecular compound RITA resulted in upregulation of ULBP2 mRNA and cell surface protein expression. Taken together, our findings define the involvement of p53 in the regulation of specific NKG2D ligands that enhance NK cell–mediated target recognition. One implication of our work is that activating p53 after adoptive transfer of NK cells might constitute an effective combinatorial strategy of NK cell–based immunochemotherapy in cancers in which wild-type p53 function is preserved. Cancer Res; 71(18); 5998–6009. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“Some missense mutant proteins can lose the transcriptional effects of wild-type genes, such as keeping PDL1 expression levels low, thereby making cancer cells more susceptible to cytotoxic T cells and NK cells, limiting the immune system’s ability to attack cancer cells.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“On the other hand, activating wild-type proteins can increase IFNγ signaling and sensitize tumors to immune checkpoint inhibitors, whereas corresponding mutant proteins can reduce the efficacy of immune checkpoint inhibitors.612–614”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [613]
In the citing paper
“In contrast, two studies reported that pharmacological reactivation of p53 in specific cell lines can stimulate the expression of ULPB2, a ligand for human NKG2D (Li et al., 2011; Textor et al., 2011).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Textor et al., 2011
In the citing paper
“Additional immunostimulatory effects linked to pharmacological p53 reactivation in cancer cells include (but are not limited to) (1) downregulation of immunomodulatory cytokines linked to tumor progression, such as IL6 (Sahin et al., 2020); (2) upregulation of NKALs (Textor et al., 2011); and (3) establishment of cellular senescence linked to an immunostimulatory SASP that favors the recruitment”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Textor et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recently, it has been shown that reactivation of p53 in mouse cancer models induced rapid tumor regression by the induction of apoptosis or cellular senescence depending on the tumor type (5).”
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J. D., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,674
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,394
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
Martin‐Fontecha, A., Thomsen, L. L., Brett, S. J., Gerard, C. J., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2004) · Nature Immunology · doi:10.1038/ni1138 · Cited by 1,351
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
An activating immunoreceptor complex formed by NKG2D and DAP10.
Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L., & Phillips, J. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,168
Natural killer cells, viruses and cancer
Cerwenka, A., & Lanier, L. L. (2001) · Nature reviews. Immunology · doi:10.1038/35095564 · Cited by 874
Self-citationSmall molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H., & Steinle, A. (2003) · Blood · doi:10.1182/blood-2003-01-0019 · Cited by 542
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature reviews. Immunology · doi:10.1038/nri2604 · Cited by 405
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 372
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Stern‐Ginossar, N., Gur, C., Biton, M., Horwitz, E. P., Elboim, M., Stanietsky, N., Mandelboim, M., & Mandelboim, O. (2008) · Nature Immunology · doi:10.1038/ni.1642 · Cited by 345
Kaeser, M. D., & Iggo, R. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012283399 · Cited by 302
Cerboni, C., Zingoni, A., Cippitelli, M., Piccoli, M., Frati, L., & Santoni, A. (2007) · Blood · doi:10.1182/blood-2006-10-052720 · Cited by 296
Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells
Waldhauer, I., & Steinle, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2520 · Cited by 245
ULBP4 is a novel ligand for human NKG2D
Chalupny, N. J., Sutherland, C. L., Lawrence, W. A., Rein‐Weston, A., & Cosman, D. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00714-9 · Cited by 202
Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR
Winter, M., Sombroek, D., Dauth, I., Moehlenbrink, J., Scheuermann, K., Crone, J., & Hofmann, T. G. (2008) · Nature Cell Biology · doi:10.1038/ncb1743 · Cited by 194
Self-citationVenkataraman, G. M., Suciu, D., Groh, V., Boss, J. M., & Spies, T. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.961 · Cited by 191
Two Human ULBP/RAET1 Molecules with Transmembrane Regions Are Ligands for NKG2D
Bacon, L., Eagle, R. A., Meyer, M., Easom, N. J. W., Young, N. T., & Trowsdale, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1078 · Cited by 184
A Cluster of Ten Novel MHC Class I Related Genes on Human Chromosome 6q24.2–q25.3
Radosavljevic, M., Cuillerier, B., Wilson, M. J., Clément, O., Wicker, S., Gilfillan, S., Beck, S., Trowsdale, J., & Bahram, S. (2002) · Genomics · doi:10.1006/geno.2001.6673 · Cited by 168
High-throughput detection and multiplex identification of cell contaminations
Schmitt, M., & Pawlita, M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp581 · Cited by 142
ULBP6/RAET1L is an additional human NKG2D ligand
Eagle, R. A., Traherne, J. A., Hair, J. R., Jafferji, I., & Trowsdale, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200939502 · Cited by 129
López‐Soto, A., Folgueras, A. R., Seto, E., & Gonzalez, S. R. (2009) · Oncogene · doi:10.1038/onc.2009.117 · Cited by 121
Sers, C., Kuner, R., Falk, C. S., Lund, P., Sueltmann, H., Braun, M., Buneß, A., Ruschhaupt, M., Conrad, J., Mang‐Fatehi, S., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24557 · Cited by 80
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
López‐Soto, A., Quiñones‐Lombraña, A., López-Arbesú, R., López‐Larrea, C., & Gonzalez, S. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604868200 · Cited by 78
Proteasome Regulation of ULBP1 Transcription
Butler, J. E., Moore, M. B., Presnell, S. R., Chan, H.-W., Chalupny, N. J., & Lutz, C. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801214 · Cited by 74
Koutsodontis, G., Vasilaki, E., Chou, W., Papakosta, P., & Kardassis, D. (2005) · Biochemical Journal · doi:10.1042/bj20041980 · Cited by 70
Textor, S., Dürst, M., Jansen, L., Accardi, R., Tommasino, M., Trunk, M. J., Porgador, A., Watzl, C., Gissmann, L., & Cerwenka, A. (2008) · International Journal of Cancer · doi:10.1002/ijc.23733 · Cited by 69
Self-citationDid Experimental Biology Die? Lessons from 30 Years of p53 Research
Madar, S., Goldstein, I., & Rotter, V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0940 · Cited by 16
Cited by
Sorted by citations
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 877
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 622
Metadata
- Authors
- Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Cerwenka, Adelheid
- Venue
- Cancer Research
- Published
- 2011-09-13
- Volume
- 71
- Issue
- 18
- Pages
- 5998-6009
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2123143632
- Cited by
- 221
- References
- 36
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 13 · 2022: 18 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 12 · 2017: 10 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 20 · 2012: 13
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- natural killer cells, NKG2D ligands, ULBP1, ULBP2, p53, wild-type p53, p53 target genes, p53 response elements, NK cell cytotoxicity, interferon-gamma, RITA, p53 reactivation
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Furans, Humans, Introns, Killer Cells, Natural, Lung Neoplasms, RNA, Messenger, Up-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, NK Cell Lectin-Like Receptor Subfamily K, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
